Skip to main content
. 2017 Oct 5;12(10):e0185862. doi: 10.1371/journal.pone.0185862

Fig 3. Combination of MEK and ERK inhibitors results in stronger suppression of MAPK pathway output and overcomes pathway reactivation.

Fig 3

(a) MAPK target genes DUSP4, DUSP6, SPRY2, SPRY4, ETV1, and ETV5 expression following 24hr treatment with the indicated doses in A549 cells. One-way ANOVA, * p<0.05, **p<0.01, *** p<0.005, **** p<0.001. (b) The combination cobimetinib and GDC-0994 in HCT116 and A549 (KRASG12S, NSCLC) cells results in stronger reduction of cyclin D1 accumulation, increased p27 levels, increased cleaved PARP levels, and, c, increased cell death at 24 hrs post-treatment at the concentrations indicated. One-way ANOVA, *** p<0.005, **** p<0.001.